Personalized mRNA Melanoma Vaccine Required a Median 64-Day Wait, and 17% of Screened Patients Lacked Usable Tumor Samples

Full INTerpath-001 results show intismeran plus Keytruda reduced melanoma recurrence or death, but survival benefit remains uncertain, while tissue adequacy, treatment delays, side effects, and cost pose practical questions.